International Isotopes INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
Radnostix Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding corporate governance, executive compensation, and related party transactions.
OQB
Radnostix Inc. reported a 6% revenue decrease and a net loss in 2025, while advancing product development and terminating a major asset sale.
OQB
International Isotopes Inc. filed an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and principal accountant fees.
OQB
International Isotopes Inc. achieved its highest annual revenue and a net income for fiscal year 2024, marking a significant turnaround from the previous year's net loss.
OQB
International Isotopes Inc. achieved its highest annual revenue in company history in 2023, driven by growth in its theranostics and nuclear medicine segments.